Priority One Canine Acquires Bio Detection K9

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.

NEOMED-LABS / Pacific Biomarkers Acquires PAIRimmune

June 6, 2019

Biotechnology

NEOMED-LABS / Pacific Biomarkers (NLPBI), an immunology-focused CRO, has acquired PAIRimmune, a preclinical immunology service provider based in Laval, Quebec. The acquisition strengthens NLPBI's assay development, ligand-binding and neutralization assay R&D capabilities, expands flow cytometry capacity, and enhances its preclinical and vaccine testing services.

Merck Acquires BioControl Systems

January 4, 2017

Food & Beverage

Merck (Merck KGaA) has acquired BioControl Systems Inc., a Bellevue, Washington-based leader in rapid food safety testing, to strengthen its applied solutions in food pathogen detection. The deal expands Merck's food and beverage offering by adding BioControl's rapid detection assays, validated kits and testing platforms to Merck's instruments and consumables portfolio; financial terms were not disclosed.

Kensington Capital Partners Acquires ONE9 Venture Capital Business

April 2, 2025

Financial Services

Kensington Capital Partners has acquired the venture capital investment business of ONE9 and taken a minority stake in ONE9 Capability Labs (with an option to acquire the remainder upon milestone achievement). ONE9's legacy investments are excluded and remain with the original vendors; the deal positions Kensington to lead investments in National Security technologies, including cybersecurity and defense-focused dual-use technologies.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.